Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28304620 | 1.00 | TSHR (0.50) | TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL23294750 | 1.00 | TSHR (0.50) | TSHRNAPRTTDP1 | |
| Benzene SCHEMBL28323090 | 0.93 | TSHR (0.43) | TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL16470497 | 0.93 | TSHR (0.43) | TSHRNAPRTTDP1 | |
| Benzene SCHEMBL7782550 | 0.91 | TSHR (0.33) | TSHRNAPRTTDP1 | |
| Benzene SCHEMBL27534065 | 0.88 | TSHR (0.32) | TSHRNAPRTTDP1 | |
| Benzene SCHEMBL27321286 | 0.88 | TSHR (0.32) | TSHRNAPRTTDP1 | |
| Benzene SCHEMBL27882227 | 0.88 | TSHR (0.32) | TSHRNAPRTTDP1 | |
| Benzene SCHEMBL27608479 | 0.88 | TSHR (0.32) | TSHRNAPRTTDP1 | |
| Hydrochlorthiazide SCHEMBL2761614 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151615-A1 | MRNA DISPLAY LIBRARIES AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-07-18 | — | — | WO | claimed |
| CN-114989160-B | Thiazole-pyridine hybrid compound and preparation method and application thereof | 中国科学院昆明植物研究所 | 2023-09-08 | — | — | CN | claimed |
| WO-2023070114-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| CN-114230574-B | N-aryl pyridine thiazolothiazole-cucurbituril compound and preparation method and application thereof | 郑州大学 | 2023-01-31 | — | — | CN | claimed |
| CN-114989160-A | Thiazole-pyridine hybrid compound and preparation method and application thereof | 中国科学院昆明植物研究所 | 2022-09-02 | — | — | CN | claimed |
| CN-114230574-A | N-aryl pyridine thiazolothiazole-cucurbituril compound and preparation method and application thereof | 郑州大学 | 2022-03-25 | — | — | CN | claimed |
| CN-104583237-B | anti-PCSK 9 antibodies and uses thereof | 奥尔德生物控股有限责任公司 | 2018-12-25 | — | — | CN | claimed |
| CN-104402910-B | Thiazole pyridine compound and preparation method thereof | 斯芬克司药物研发（天津）股份有限公司 | 2017-02-08 | — | — | CN | claimed |
| CN-103724360-B | Pyridine (or benzene) thiazolium compounds and intermediate, preparation method and application | 上海医药工业研究院 | 2016-08-10 | — | — | CN | claimed |
| CN-103524535-B | There is the Amido thiazole-pyridine heterocycle compound of activity of hedgehog path antagonist | 苏州云轩医药科技有限公司 | 2016-07-13 | — | — | CN | claimed |
| CN-104402910-A | Thiazole pyridine compound and preparation method thereof | SPHINX SCIENT LAB CORP | 2015-03-11 | — | — | CN | claimed |
| CN-102112473-B | Pyrrolidinyl-alkyl-amide derivatives, process for their preparation and their therapeutic use as CCR3 receptor ligands | SANOFI AVENTIS | 2014-08-20 | — | — | CN | claimed |
| CN-103958473-A | Amide compound, composition and application thereof | ADVINUS THERAPEUTICS LTD | 2014-07-30 | — | — | CN | claimed |
| CN-103140466-A | Process for preparing compound by novel sandmeyer-like reaction using nitroxide radical compound as reaction catalyst | DAIICHI SANKYO CO LTD | 2013-06-05 | — | — | CN | claimed |
| CN-103086981-A | New compounds | NOVARTIS AG | 2013-05-08 | — | — | CN | claimed |
| US-20120270875-A1 | PYRIMIDINE AMIDE COMPOUNDS | GILLESPIE PAUL (US) | 2012-10-25 | — | — | US | claimed |
| WO-2012123467-A1 | PYRIMIDINE AMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | claimed |
| CN-1845736-A | Methods related to the treatment of mucosal associated conditions | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-11 | — | — | CN | claimed |
| CN-1587346-A | Non-conjugate high molecular electroluminescent material and its preparing method | XU LIANGHENG (CN) | 2005-03-02 | — | — | CN | claimed |
| EP-0214029-B1 | 1-DETHIA-2-THIA CEPHALOSPORANIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1992-03-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270875-A1 | PYRIMIDINE AMIDE COMPOUNDS | UMPS, TYMS, DPYD | TSHR 2473/4885NAPRT 38/4885TDP1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.